Cargando…

Assessment of rAAVrh.74.MHCK7.micro-dystrophin Gene Therapy Using Magnetic Resonance Imaging in Children With Duchenne Muscular Dystrophy

This case-control study uses magnetic resonance imaging and spectroscopy to evaluate the association between treatment with recombinant adeno-associated virus serotype rh74 (rAAVrh74) and muscle quality in children with Duchenne muscular dystrophy.

Detalles Bibliográficos
Autores principales:	Willcocks, Rebecca J., Forbes, Sean C., Walter, Glenn A., Sweeney, Lee, Rodino-Klapac, Louise R., Mendell, Jerry R., Vandenborne, Krista
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783546/ https://www.ncbi.nlm.nih.gov/pubmed/33394000 http://dx.doi.org/10.1001/jamanetworkopen.2020.31851

Ejemplares similares

Dose-Escalation Study of Systemically Delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx Mouse Model of Duchenne Muscular Dystrophy
por: Potter, Rachael A., et al.
Publicado: (2021)

Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial
por: Mendell, Jerry R., et al.
Publicado: (2020)

Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy
por: Goedeker, Natalie L., et al.
Publicado: (2023)

Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength
por: Martin, Paul T., et al.
Publicado: (2021)

A first-in-human phase I/IIa gene transfer clinical trial for Duchenne muscular dystrophy using rAAVrh74.MCK.GALGT2
por: Flanigan, Kevin M., et al.
Publicado: (2022)

Expression and function of four AAV-based constructs for dystrophin restoration in the mdx mouse model of Duchenne muscular dystrophy
por: Potter, Rachael A., et al.
Publicado: (2023)

An Isolated Limb Infusion Method Allows for Broad Distribution of rAAVrh74.MCK.GALGT2 to Leg Skeletal Muscles in the Rhesus Macaque
por: Xu, Rui, et al.
Publicado: (2018)

A translational approach for limb vascular delivery of the micro-dystrophin gene without high volume or high pressure for treatment of Duchenne muscular dystrophy
por: Rodino-Klapac, Louise R, et al.
Publicado: (2007)

Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States
por: Klimchak, Alexa C., et al.
Publicado: (2023)

Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy
por: Naidoo, Michael, et al.
Publicado: (2019)

Therapeutic Strategies for Dystrophin Replacement in Duchenne Muscular Dystrophy
por: Happi Mbakam, Cedric, et al.
Publicado: (2022)

Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy
por: Al-Zaidy, Samiah A., et al.
Publicado: (2015)

rAAVrh74.MCK.GALGT2 Demonstrates Safety and Widespread Muscle Glycosylation after Intravenous Delivery in C57BL/6J Mice
por: Zygmunt, Deborah A., et al.
Publicado: (2019)

Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy
por: Kemaladewi, Dwi U, et al.
Publicado: (2011)

The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

The discovery of dystrophin, the protein product of the Duchenne muscular dystrophy gene
por: Hoffman, Eric P.
Publicado: (2020)

Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy
por: Frank, Diane E., et al.
Publicado: (2020)

Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy
por: Mendell, Jerry R., et al.
Publicado: (2023)

Longitudinal changes in cardiac function in Duchenne muscular dystrophy population as measured by magnetic resonance imaging
por: Batra, Abhinandan, et al.
Publicado: (2022)

Long-term treatment with eteplirsen in nonambulatory patients with Duchenne muscular dystrophy
por: Alfano, Lindsay N., et al.
Publicado: (2019)

Intellectual Ability in the Duchenne Muscular Dystrophy and Dystrophin Gene Mutation Location
por: Milic Rasic, V, et al.
Publicado: (2015)

Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy
por: Duan, Dongsheng
Publicado: (2018)

Skeletal muscle magnetic resonance biomarkers correlate with function and sentinel events in Duchenne muscular dystrophy
por: Barnard, Alison M., et al.
Publicado: (2018)

A Roadmap to Newborn Screening for Duchenne Muscular Dystrophy
por: Al-Zaidy, Samiah A., et al.
Publicado: (2017)

Suitability of external controls for drug evaluation in Duchenne muscular dystrophy
por: Goemans, Nathalie, et al.
Publicado: (2020)

Dystrophin Gene Mutation Location and the Risk of Cognitive Impairment in Duchenne Muscular Dystrophy
por: Taylor, Peter J., et al.
Publicado: (2010)

Characterization of Dystrophin Deficient Rats: A New Model for Duchenne Muscular Dystrophy
por: Larcher, Thibaut, et al.
Publicado: (2014)

Deletion pattern in the dystrophin gene in Duchenne muscular dystrophy patients in northeast India
por: Basumatary, Lakshya J, et al.
Publicado: (2013)

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2019)

Restorative treatments of dystrophin expression in Duchenne muscular dystrophy: A systematic review
por: Pascual‐Morena, Carlos, et al.
Publicado: (2020)

Investigating the role of dystrophin isoform deficiency in motor function in Duchenne muscular dystrophy
por: Chesshyre, Mary, et al.
Publicado: (2022)

Participation and quality of life in children with Duchenne muscular dystrophy using the International Classification of Functioning, Disability, and Health
por: Bendixen, Roxanna M, et al.
Publicado: (2012)

Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy
por: Farrokhi, Vahid, et al.
Publicado: (2021)

Magnetic Resonance Assessment of Hypertrophic and Pseudo-Hypertrophic Changes in Lower Leg Muscles of Boys with Duchenne Muscular Dystrophy and Their Relationship to Functional Measurements
por: Vohra, Ravneet S., et al.
Publicado: (2015)

Evaluation of exon-skipping strategies for Duchenne muscular dystrophy utilizing dystrophin-deficient zebrafish
por: Berger, Joachim, et al.
Publicado: (2011)

Influence of full-length dystrophin on brain volumes in mouse models of Duchenne muscular dystrophy
por: Kogelman, Bauke, et al.
Publicado: (2018)

Dystrophin Dp116: A Yet to Be Investigated Product of the Duchenne Muscular Dystrophy Gene
por: Matsuo, Masafumi, et al.
Publicado: (2017)

Startle responses in Duchenne muscular dystrophy: a novel biomarker of brain dystrophin deficiency
por: Maresh, Kate, et al.
Publicado: (2022)

Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates
por: Borel, Florie, et al.
Publicado: (2016)

Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy
por: Larkindale, Jane, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k7mv0m23vc98d81h9o69ef13bj